1. Home
  2. LCFY vs ENVB Comparison

LCFY vs ENVB Comparison

Compare LCFY & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$3.59

Market Cap

8.3M

Sector

N/A

ML Signal

HOLD

Logo Enveric Biosciences Inc.

ENVB

Enveric Biosciences Inc.

HOLD

Current Price

$1.40

Market Cap

8.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCFY
ENVB
Founded
2009
1994
Country
Australia
United States
Employees
18
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
8.1M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
LCFY
ENVB
Price
$3.59
$1.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.6K
140.0K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$39,914,675.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.56
52 Week High
$7.75
$13.25

Technical Indicators

Market Signals
Indicator
LCFY
ENVB
Relative Strength Index (RSI) 46.65 34.24
Support Level $2.83 $0.58
Resistance Level $4.02 $2.13
Average True Range (ATR) 0.26 0.15
MACD 0.03 0.03
Stochastic Oscillator 60.48 25.45

Price Performance

Historical Comparison
LCFY
ENVB

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Share on Social Networks: